Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 457-320-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 February 1998 - 1 May 1998
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- Deviations:
- yes
- Remarks:
- Slight protocol deviations were noted in the study report (including a dosing accident and subsequent replacement animals), but it was stated that "it is unlikely that these protocol exceptions adversely affected the results or integrity of the study"
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EU Method B.9 (Repeated Dose (28 Days) Toxicity (Dermal))
- Deviations:
- yes
- Remarks:
- as above
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Test material form:
- liquid
- Details on test material:
- Batch: MRD-98-158
67% ai in 33% refined base oil
Constituent 1
- Specific details on test material used for the study:
- 67% purity
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Portage, MI
- Age at study initiation: Males approx 8 weeks; females approx. 9 weeks
- Weight at study initiation: Males 248-275 g; females 200-232 g
- Fasting period before study: none
- Housing: Singly in suspended stainless steel and wire mesh cages
- Diet: ad libitum, PMI Certified Rodent Diet Meal 5002, PMI Feeds Inc, Richmond, Indiana
- Water: ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-22
- Humidity (%): 30-70
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): approx. 12/12
IN-LIFE DATES: From: 19 March 1998 To: 1 May 1998
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- peanut oil
- Details on exposure:
- Method of administration:
Dermal
TEST SITE
- % coverage: approx. 10% of total body surface
- Type of wrap if used: porous gauze dressing secured with non-irritating tape and wrapped with COBAN
- Time intervals for shavings or clippings: approx. 24 h prior to initial administration and at least once weekly
REMOVAL OF TEST SUBSTANCE
- Washing (if done): removed by gently wiping the exposure site with peanut oil and a paper towel.
- Time after start of exposure: at least 6 h
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 0, 100, 300 and 1000 mg/kg bw/day
- Constant volume or concentration used: each dose group used a different concentration, and individual dose volumes were adjusted weekly based on the most recent body weights
VEHICLE
- Justification for use and choice of vehicle (if other than water): Test substance was soluble in peanut oil at the concentrations used in the study
- Amount(s) applied (volume or weight with unit): 2.0 ml/kg bw
- Concentration (if solution): no data
USE OF RESTRAINERS FOR PREVENTING INGESTION: no - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of the test substance in peanut oil were received for analysis at nominal concentrations ranging from 1 % to 75%, diluted with n-heptane to give final nominal concentrations between 0.08% and 0.26% and analyzed for uniformity, stability, and concentration verification using reverse phase High Performance Liquid Chromatography (HPLC). The uniformity of the test substance in peanut oil was evaluated for samples mixed on 18 March 1998, the stability was evaluated over an eight-day period for samples mixed on 18 March 1998 and the concentration verification was evaluated for the samples mixed on 19 March 1998 and 3 April 1998. Satisfactory uniformity was observed, stability data indicated that the test substance diluted in peanut oil was stable at room temperature for at least eight days and concentration verification analyses indicated that the test substance concentration was within 10% of the nominal value.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- at least 6 h/day, 7 days/week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10/sex/dose in the control and high-dosed groups and 5/sex/dose in the low and mid-dosed groups
- Control animals:
- yes, sham-exposed
- Details on study design:
- - Dose selection rationale: Based on a 1-week range-finding study which showed no signs of overt toxicity at the limit dose level of 1000 mg/kg bw when diluted in peanut oil. The low- and mid-dose levels were selected to provide a logarithmic progression of dosages.
- Rationale for animal assignment (if not random): After determination of suitability based on health, body weight and other abnormalities, a computer generated sorting programme was used
- Rationale for selecting satellite groups: no data
- Post-exposure recovery period in satellite groups: 14 days - Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily from Monday-Friday and once daily on Saturdays, Sundays and holidays
- Cage side observations included: viability
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily during the test period
DERMAL IRRITATION (if dermal study): Yes
- Time schedule for examinations: Prior to dosing on days 0, 1, 4, 7, 11, 14, 18, 21 and 25; also after sleeve removal on day 0 and prior to blood collection on day 28; additional dermal evaluations for satellite animals on days 32, 35, 39 and 42. All dermal evaluations performed according to the Draize method of scoring.
BODY WEIGHT: Yes
- Time schedule for examinations: Prior to initiation of dosing for group allocation, on the day of initiation of dosing and on days 7, 14, 21 and 27; body weights for satellite animals also recorded on days 35 and 41.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Main study animals - day 28, satellite animals - day 42
- Anaesthetic used for blood collection: Yes - methoxyflurane
- Animals fasted: Yes
- How many animals: All main study and all satellite animals
- Parameters checked in Table 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Main study animals - day 28, satellite animals - day 42
- Animals fasted: Yes
- How many animals: All main study and all satellite animals
- Parameters checked in Table 2 were examined.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
OTHER: No - Sacrifice and pathology:
- GROSS PATHOLOGY:
A full macroscopic postmortem examination performed on all animals, and required organs were preserved.
HISTOPATHOLOGY:
(see table 3 below) - Other examinations:
- ORGAN WEIGHTS:
Liver, kidneys, testes, adrenals and brain were weighed from all main study animals on day 28 and all satellite animals on day 42 - Statistics:
- Bartlett's Test was performed to determine if the dose groups had equal variance (Snedecor and Cochran, 1989). If the variances were equal, the testing was done using parametric methods, otherwise nonparametric techniques were used.
Parametric procedures - a standard one way ANOVA using the F distribution to assess significance was used (Snedecor and Cochran, 1989). If significant differences among the means were indicated, Dunnett's Test was used to determine which treatment groups differed significantly from control (Dunnett, 1964). In addition to the ANOVA, a standard regression analysis for linear response in the dose groups was performed. This also tested for linear lack of fit in the model.
Non parametric procedures - the test of equality of means was performed using the Kruskal-Wallis Test (Hollander and Wolfe, 1973). If significant differences among the means were indicated, Dunn's Summed Rank Test was used to determine which treatment groups differed significantly from the control (Hollander and Wolfe, 1973). In addition to the Kruskal-Wallis Test, Jonckheere's Test for monotonic trend in the dose response was performed (Hollander and Wolfe, 1973).
Bartlett's Test was conducted at the 1% level of significance and all others at the 5% and 1% level of significance.
The satellite group's recovery parameters were compared using the statistical t-test (Dixon and Massey, 1969).
The statistical tests were considered appropriate.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related clinical signs of toxicity at any dose level tested.
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Incidental findings were limited to occasional scabs among both sexes. Slight transient dermal irritation was the only significant observation and was limited to erythema, desquamation and/or oedema, observed primarily in the top-dosed males and in all groups of females during week 1 and starting on day 4. Erythema and/or oedema was also observed in two control females and desquamation in 3 control females. Irritation was scored according to Draize, 1959. The dermal effects in the 100 and 300 mg/kg bw/day groups did not show a noticeable dose-response difference from the controls (though, treatment-related dermal histopathology was seen in 300 mg/kg bw/day animals).
- Mortality:
- no mortality observed
- Description (incidence):
- All main study and satellite animals survived to terminal sacrifice
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- There were no statistically significant differences in mean body weight or mean body weight gain between treated and control females at any interval. All male animals showed increases in body weight over their initial values. Mean body weight gain of the high-dosed males was significantly decreased on day 27 when compared with the controls (p=0.05) and similar significant decreases were also seen between days 0-7 and 14-21. This decrease was transient with the mean body weight being comparable to the controls following the recovery period and was not considered to be biologically or toxicologically important.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences in mean food consumption between the treated and control main study or satellite animals of either sex.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- No statistically significant differences in haematological parameters were seen in any of the main study animals. Following the recovery period, mean white blood cells and mean absolute monocytes were significantly decreased in the males when compared with the controls however these were not considered to be clinically significant or related to the test substance.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- No biologically meaningful differences in serum chemistry parameters were seen in any of the main study animals and there were no statistically significant differences following the recovery period.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No differences in mean absolute, relative organ/body, or relative organ/brain weights were seen which were considered to be treatment-related. A statistically significant increase in the mean absolute adrenal weight, mean adrenal:body weight ratio and mean adrenal:brain weight ratio amongst the top-dosed females when compared to the controls in the main study, was not considered of relevance due to the absence of a clear dose response. Following recovery, there was a statistically significant increase in mean relative kidney:body weight ratio among the top-dosed males when compared to the controls however this difference was small and, in the absence of similar findings in the main study, was considered spurious and unrelated to the test substance.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No gross pathological changes were observed in any organ or tissue to indicate any type of systemic toxicity. Discoloured livers were frequently observed in all groups including the controls in both the main study and following the recovery period. However, this was most likely caused by the wrapping procedure and not considered to be related to the test substance.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Microscopic changes were seen in the treated skin area of the mid- and high-dosed animals in the main study. These changes consisted of acanthosis and hyperkeratosis of the epidermis and an associated sebaceous gland hyperplasia. A decrease in the degree and incidence of these effects was seen during the recovery phase, indicating that the changes were reversible. Changes were also noted, to a lesser degree, in the control and low-dosed animals and were considered to have been due to the repeated shaving and wrapping of the torso and/or a mild irritating effect of the test substance. No further microscopic changes were observed in any of the other organs or tissues examined.
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
All main study and satellite animals survived to terminal sacrifice and showed no treatment-related clinical signs of toxicity at any dose level tested. Incidental findings were limited to occasional scabs among both sexes. Slight
transient dermal irritation was the only significant
observation and was limited to erythema, desquamation and/or oedema, observed primarily in the top-dosed males and in all groups of females
during week 1 and starting on day 4. Erythema and/or oedema was also observed in
two control females and desquamation in 3 control females. Irritation was scored according to Draize, 1959. The dermal effects in the 100 and 300 mg/kg bw/day groups did not show a noticeable dose-response difference from the controls (though, treatment-related dermal histopathology was seen in 300 mg/kg bw/day animals).
BODY WEIGHT AND WEIGHT GAIN: There were no statistically significant differences in mean body weight or mean body weight gain between treated and control females at any interval. All male animals showed increases in body weight over their initial values. Mean body weight gain of the high-dosed males was significantly decreased on day 27 when compared with the controls (p=0.05) and similar significant decreases were also seen between days 0-7 and 14-21. This decrease was transient with the mean body weight being comparable to the controls following the recovery period and was not considered to be biologically or toxicologically important.
FOOD CONSUMPTION: There were no statistically significant differences in mean food consumption between the treated and control main study or satellite animals of either sex.
HAEMATOLOGY: No statistically significant differences in haematological parameters were seen in any of the main study animals. Following the recovery period, mean white blood cells and mean absolute monocytes were significantly decreased in the males when compared with the controls however these were not considered to be clinically significant or related to the test substance.
CLINICAL CHEMISTRY: No biologically meaningful differences in serum chemistry parameters were seen in any of the main study animals and there were no statistically significant differences following the recovery period.
ORGAN WEIGHTS: No differences in mean absolute, relative organ/body, or relative organ/brain weights were seen which were considered to be treatment-related. A statistically significant increase in the mean absolute adrenal weight, mean adrenal:body weight ratio and mean adrenal:brain weight ratio amongst the top-dosed females when compared to the controls in the main study, was not considered of relevance due to the absence of a clear dose response. Following recovery, there was a statistically significant increase in mean relative kidney:body weight ratio among the top-dosed males when compared to the controls however this difference was small and, in the absence of similar findings in the main study, was considered spurious and unrelated to the test substance.
GROSS PATHOLOGY: No gross pathological changes were observed in any organ or tissue to indicate any type of systemic toxicity. Discoloured livers were frequently observed in all groups including the controls in both the main study and following the recovery period. However, this was most likely caused by the wrapping procedure and not considered to be related to the test substance.
HISTOPATHOLOGY: Microscopic changes were seen in the treated skin area of the mid- and high-dosed animals in the main study. These changes consisted of acanthosis and hyperkeratosis of the epidermis and an associated sebaceous gland hyperplasia. A decrease in the degree and incidence of these effects was seen during the recovery phase, indicating that the changes were reversible. Changes were also noted, to a lesser degree, in the control and low-dosed animals and were considered to have been due to the repeated shaving and wrapping of the torso and/or a mild irritating effect of the test substance. No further microscopic changes were observed in any of the other organs or tissues examined.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 670 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- In a GLP study conducted in general agreement with OECD guideline 410, the 28-day dermal NOAEL in the rat was 1000 mg/kg bw/day (the highest tested dose), equivalent to 670 mg/kg bw/day active ingredient.
- Executive summary:
In a GLP study conducted in general agreement with OECD guideline 410, the repeated dermal toxicity of a compound which is both chemically and structurally similar to EC# 457-320-2 was determined in Crl:CD(R) BR rats. Groups of 5 male and 5 female animals were treated, under covered contact, to the clipped skin with 0, 100, 300 or 1000 mg/kg bw/day (in peanut oil) for 28 days. The residual test substance was removed by gently wiping with peanut oil and a paper towel after at least 6 hours. Additional groups of 5 animals/sex were similarly treated with 0 or 1000 mg/kg bw/day and allowed to recover for 14 days to test for reversibility, persistence or delayed occurrence of toxic effects. Individual doses were adjusted weekly based on the most recent body weights.
Dermal application of the test substance under the conditions of this study elicited no signs of systemic toxicity. There were no adverse clinical signs, post-mortem findings, non-dermal treatment-related histopathological findings, biologically significant changes in body weight, food consumption or absolute/relative organ weights, or clinically significant changes in hematology, clotting potential or serum chemistry which were related to treatment. Treatment-related findings were limited to microscopic changes in the treated area of the skin of animals in the 300 and 1,000 mg/kg bw/day groups. All other changes observed were considered to be either incidental or indirectly related to experimental manipulation (i.e. wrapping). The NOAEL for the test material under the conditions of this study was determined to be 1000 mg/kg bw/day. The test material consisted of 67% active substance in refined base oil; therefore, the NOAEL for the active substance was 670 mg/kg bw/day. The NOAEL for local effects at the site of administration is concluded to be 100 mg/kg bw/day, however, after correction for purity of 67% the local NOAEL is 67 mg/kg bw/day.
In view of the structural and chemical similarities, it is considered that the results of this study can be used for read-across to EC# 457-320-2.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Napriek tomu, že agentúra ECHA poskytuje online veľa materiálov vo vašom jazyku, časť tejto stránky je k dispozícii len v anglickom jazyku. Viac informácií o praxi v oblasti viacjazyčnosti v agentúre ECHA.
Internetová stránka agentúry ECHA Stránka nie je plne podporovaná v prehliadači Internet Explorer 7 (a starších verziách). Aktualizujte si prehliadač Internet Explorer na novšiu verziu.
Táto webová lokalita využíva súbory cookies, aby sme vám zabezpečili najlepšie používateľske prostredie na našich webových stránkach.
Viac informácií ako využívame súbory cookies.